Copenhagen, 2011-04-28 16:25 CEST (GLOBE NEWSWIRE) -- Company Announcement

No. 06/2011



     Zealand Pharma - Annual general meeting held on Thursday 28 April 2011





Copenhagen, 28 April 2011 - Today, Zealand Pharma A/S has held its annual
general meeting. 



The report from the management on the company's activities in the past
financial year was noted by the general meeting. 



The audited annual report, including the board of directors' fee for the
financial year 2010, was approved. 



It was resolved to carry the consolidated loss of DKK 104,634,348.51 forward to
next year. 



Daan J. Ellens, Peter Benson, Alain Munoz and Florian Reinaud were re-elected
as board members. Jutta of Rosenborg and Jørgen Lindegaard were elected new
members of the board of directors. 



Grant Thornton, Incorporated State Authorised Public Accountants was re-elected
as the company's auditor. 



The board of directors was granted the authorisation, until the company's next
annual general meeting to acquire the company's own shares for up to 10 per
cent of the company's existing share capital at any time. The price of the
shares may not divide with more than 10 per cent from the closing price at
NASDAQ OMX Copenhagen A/S at the time of purchase. 



The remuneration policy, including the general guidelines for incentive
remuneration for the board of directors and the executive management, was
approved. Further, the "General guidelines for incentive remuneration to the
management of Zealand Pharma A/S", as adopted at the general meeting in
November 2010, were reaffirmed. 



The fee to the board of directors for the financial year 2011 was approved as
proposed. The board of directors had proposed that board members receive a
fixed cash payment of DKK 150,000 and that the chairman receives a fixed cash
payment of DKK 300,000. In addition, the chairman of a board sub-committee
receives DKK 15,000 per meeting and preparation day, up to a maximum of DKK
75,000 per year. 



For further information, please contact:

David Solomon, President and Chief Executive Officer - Tel: +45 4328 1200

Hanne Leth Hillman, Vice President, Head of IR and Corporate Communications
- Tel: +45 5060 3689



About Zealand Pharma

Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) Scandinavian based
biopharmaceutical company with a mature and growing clinical pipeline of
innovative peptide drugs. The company's lead product candidate is a once-daily
GLP-1 in late-stage Phase III development for the treatment of Type 2 Diabetes
in collaboration with sanofi-aventis. Zealand Pharma also has several other
collaboration and licensing partnerships, including a license agreement with
Helsinn Healthcare on a clinical stage GLP-2 drug for the treatment of
Chemotherapy and Radiotherapy Induced Diarrhoea. 

Zealand Pharma has unique expertise in peptide discovery and optimization and
in the development of novel peptide drugs with favourable therapeutic
attributes. The company targets metabolic (diabetes and obesity),
gastrointestinal and cardiovascular diseases, where existing treatments fail to
adequately serve patient needs and where the market potential for improved
treatments through the use of peptide drugs is high. All of Zealand Pharma's
product candidates have been identified through the company's own drug
discovery activities. The company is headquartered in Copenhagen and has
approximately 90 employees. For more information please visit
www.zealandpharma.com.